## FIG. 1

Expose for approximately 24 hrs 10<sup>7</sup> melanoma cells to 10<sup>6</sup> PFU of recombinant vaccinia virus encoding human IL-2 (rIL-2VV) Break virus-exposed melanoma cells by sonication and isolate enucleated cytosol, cell membranes, and virus particles. UV-irradiate obtained melanoma sonicate (MS) and pool at least five melanoma lines' sonicates at a concentration corresponding to 10<sup>7</sup> original cells/ml. Freeze 1ml vials at -70°C. Isolate patient's own dendritic and monocytic cells (DC/M) from 50 ml of peripheral blood. Propagate DC/M cells in vitro in the presence of IL-4 and GM-CSF. Prepare pulsed DC/M cells by adding thawed melanoma sonicate (MS) for about 18 hrs (overnight). Isolate DC/M-MS cells. Inject subcutaneously 107 PFU of live vaccinia virus encoding IL-2 (rIL-2VV) in about 4-6 sites proximal to patient's regional lymph nodes. Divide a vial containing 1-5 X 10<sup>6</sup> pulsed DC/M-MS cells into approximately 4-6 doses and inject into the same sites as rIL-2VV. Repeat injections for three months at biweekly intervals (induction phase) followed by injections every 3 months for 1-2 years or until recurrence. Monitor clinical and immune response parameters. ...




FIG. 2




FIG. 3




FIG. 4




FIG. 5





FIG. 6



nge, green HG. 7